News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Staff September 11, 2023 Iframe sync Post navigation Previous: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNext: Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors More Stories Diagnostics EHR Healthcare News Pharmaceutical Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope Staff January 11, 2026 Clinical Trial DNA News Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response Staff January 11, 2026 Cancer Clinical Trial Healthcare News Pharmaceutical Pregnancy Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand Staff January 11, 2026
